EBCC: New Standard Suggested for Metastatic Breast Cancer (CME/CE)

posted on Mar 28 by MedPage Today OB/Gyn in the Uncategorized category BARCELONA (MedPage Today) -- Patients with HER2-positive metastatic breast cancer lived just as long, but with significantly less toxicity, when treated with vinorelbine (Navelbine) and trastuzumab (Herceptin) than with docetaxel (Taxotere) and trastuzumab, a randomized trial showed.